BioSpace News Archive

Aerie Pharmaceuticals, Inc announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 1:30 p.m. Eastern Time in New York, NY.

Nestlé Health Science today announced that it has entered into a global strategic partnership with Amazentis, a Swiss-based pioneer in science-driven nutritional health.

Aldeyra Therapeutics, Inc. announced enrollment of the first patient into the RENEW Phase 3 clinical trial of topical ocular reproxalap for the treatment of dry eye disease.

Data demonstrate that UNITE, as a nucleic acid platform, may enhance antitumor immunity

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, today announced that the first patient was dosed in the clinical trial of its next-generation anti-CTLA-4 antibody (AGEN1181).

American College of Clinical Pharmacology® & Cardiac Safety Research Consortium are pleased to announce the publication of their first co-authored paper, “The Potential Role of the J-Tpeak Interval in Pro-arrhythmic Cardiac Safety − Current State-of-the-Science from the American College of Clinical Pharmacology and the Cardiac Safety Research Consortium,” in The Journal of Clinical Pharmacology.

Infinity Pharmaceuticals, Inc. announced that Adelene Perkins, Infinity Pharmaceutical’s Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 3:30 p.m. ET at the Westin NY Grand Central Hotel in New York, NY.

Uterine fibroid embolization (UFE) effectively treats uterine fibroids with fewer post-procedure complications compared to myomectomy, according to new research presented at the Society of Interventional Radiology’s 2019 Annual Scientific Meeting.

Comprehensive Outcomes Management Technologies, LLC received a federal grant as part of a musculoskeletal injury rehabilitation research program funded by the Defense Health Agency.

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced pre-clinical data supporting the immunological effects of MTL-CEBPA and its benefits in combination with other anti-cancer interventions including sorafenib, anti-PD1 checkpoint inhibition and radiofrequency ablation.